Hims & Hers Health Inc. Aktie News

SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced that it has entered into a definitive agreement to acquire YourBio Health, Inc., a Boston-based pioneer in capillary whole blood sampling technology. Powered by YourBio's advanced blood sampling devices, the acquisition will help accelerate efforts to redefin...

New York, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- GraniteShares, a one of the leading issuer of exchange-traded funds (ETFs), today announced the launch of two new additions to its growing YieldBOOST ™ family, offering investors additional ways to access income opportunities across high-growth and highly followed segments of the equity market. Ticker Fund Underlying Company RTYY GraniteShares Yie...

The regulatory changes surrounding the weight loss treatment industry are having a large impact on Hims & Hers (HIMS 1.83%) stock.

Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product offerings and logistics, driving subscriber and revenue growth, despite near-term margin compression and increased capital expenditures. The upcoming Zava acquisition and potential regulatory changes...

Several big-name stocks just announced notable increases to their share buyback programs. These actions signal confidence, indicating that these companies' management teams may see value in their stocks.

Hims & Hers maintains its long-term Buy rating, despite recent stock volatility and slower subscriber growth. HIMS continues to expand its platform beyond GLP-1s, investing heavily in verticalization and new offerings like Labs via Quest Diagnostics. Short-term free cash flow growth will be slower due to increased capex, but management guides for $2.3B revenue in 2025 and $6.5B by 2030.

Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie NYSE: ABBV, Eli Lilly NYSE: LLY, Pfizer NYSE: PFE, and Merck NYSE: MRK—and their lineup of game-changing drugs—receive the lion's share of attention.

Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and cosmetics, that address acne, hyperpigmentation and eczema and range in price from about $29 to around $59.